Артериальная гипертензия журнал официальный сайт

Артериальная гипертензия журнал официальный сайт

1. Meier SM, Mattheisen M, Mors O, Mortensen PB, Laursen TM, Penninx BW. Increased mortality among people with anxiety disorders: total population study. Br J Psychiatry. 2016;209 (3):216–21. doi: 10.1192/bjp.bp.115.171975

2. Laursen TM, Musliner KL, Benros ME, Vestergaard M, Munk-Olsen T. Mortality and life expectancy in persons with severe unipolar depression. J Affect Disord. 2016;193:203–7. doi: 10.1016/j.jad.2015.12.067

3. Смулевич А. Б. Депрессии в общей медицине. М.: МИА, 2010. 256 с. [Smulevich AB. Depression in general medicine. Moscow: MIA, 2010. 256 p. In Russian].

4. Чазов Е. И., Оганов Р. Г., Погосова Г. В., Шальнова С. А., Ромасенко Л. В., Щуров Д. В. Клинико-эпидемиологическая программа изучения депрессии в кардиологической практике у больных артериальной гипертонией и ишемической болезнью сердца (КООРДИНАТА): результат многоцентрового исследования. Кардиология. 2007;3:28– 37. [Chazov EI, Oganov RG, Pogosova GV, Shal’nova SA, Romasenko LV, Deev AD. Clinical and epidemiological study of depression program in cardiology practice in patients with hypertension and coronary heart disease (KOORDINATA): results of a multicenter study. Kardiologiia. 2007;3:28–37. In Russian].

5. Moise N, Davidson KW, Chaplin W, Shea S, Kronish I. Depression and clinical inertia in patients with uncontrolled hypertension. J Am Med A Intern Med. 2014;174(5):818–9. doi: 10.1001/jamainternmed.2014.115

6. Васюк Ю. А., Довженко Т. В., Школьник Е. Л. Особенности патогенетической взаимосвязи депрессии и сердечно-сосудистых заболеваний. Психические расстройства в общей медицине. 2007;2(1):8–12. [Vasjuk JuA, Dovzhenko TV, Shkol’nik EL. Features pathogenetic relationships of the depression and cardiovascular diseases. Mental Disorders in General Medicine. 2007;2(1):8–12. In Russian].

7. Дроздецкий С. И., Кучин К. В., Макаров В. Н., Боряк А. М. Тревожно-депрессивные расстройства у больных артериальной гипертензией. Клиническая медицина. 2010;1 (приложение):27–28. [Drozdeckij SI, Kuchin KV, Makarov VN, Borjak AM. Anxiety and depressive disorders in patients with arterial hypertension. Klinicheskaya Meditsina = Clinical Medicine. 2010;1(annex):27–28. In Russian].

8. Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis. 2016;58 (5):514–28. doi: 10.1016/j.pcad.2015.11.003

9. Тарловская Е. И., Козиолова Н. А., Чесникова А. И. Проблема лекарственного взаимодействия в кардиологической практике: что должен учитывать врач? Российский кардиологический журнал. 2015;12(128):91–101. doi: 10.15829/1560–4071– 2015–12–91–101. [Tarlovskaja EI, Koziolova NA, Chesnikova AI. The problem of drug interactions in cardiology practice: that the doctor must take into account? Rossiyskiy Kardiologicheskiy Zhurnal = Russian Cardiology Journal. 2015;12(128):91–101. doi: 10.15829/1560–4071–2015–12–91–101. In Russian].

10. Федеральные клинические рекомендации по диагностике и лечению рекуррентного депрессивного расстройства. 2013. http://psychiatr.ru/. [Federal guidelines for the diagnosis and treatment of recurrent depressive disorder. 2013. URL: http://psychiatr.ru/. In Russian].

11. Serretti A, Olgiati P. Biochemistry of depressive disorders. Role of serotonin, amino acid neurotransmitters, substance P and neurosteroids. Clinical Neuropsychiatry. 2008;5(5):225– 41.

12. Carney RM, Freedland KE, Veith RC. Depression, the autonomic nervous system, and coronary heart disease. Psychosom. Med. 2005;67(1):29–33.

13. Bogner HR, de Vries HF. Integration of depression and hypertension treatment: a pilot, randomized controlled trial. Ann Fam Med. 2008;6(4):295–301.

14. Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Preference and Adherence. 2012;6:853.

15. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;13;116(6):976–90. doi: 10.1161/CIRCRESAHA. 116.303604

16. Hildingh C, Baigi A. The association among hypertension and reduced psychological well-being, anxiety and sleep disturbances: a population study. Scand J Caring Sci. 2010;24 (2):366–71. doi: 10.1111/j.1471–6712.2009.00730.x

17. Clark AJ, Salo P, Lange T, Jennum P, Virtanen M, Pentti J et al. Onset of impaired sleep and cardiovascular disease risk factors: a longitudinal study. Sleep. 2016;39(9):1709–18. doi: 10.5665/sleep.6098

18. Кукес В. Г., Остроумова О. Д., Стародубцев А. К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum. 2006;8 (11):113–117. [Kukes VG, Ostroumova OD, Starodubcev AK. Calcium channel blockers: modern aspects of usage in cardiology. Consilium medicum. 2006;8 (11):113–117. In Russian].

19. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–1225. doi:10.1161/CIRCULATIONAHA.105.595496

20. Thomas van Sloten, Mitchell GF, Sigurdsson S. Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGESReykjavik Study. J Psychiatry Neuroscience. 2015;41(1):140334.

21. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457. doi: 10.1016/j.biopsych.2009.09.033

22. Wang Y, Zhang H, Chai F, Liu X, Berk M. The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl‑2 during myocardial ischemia/reperfusion in a model of rats with depression. BMC Psychiatry. 2014;14:349. doi: 10.1186/s12888–014– 0349‑x

23. Seldenrijk A, van Hout HP, van Marwijk HW. Depression, anxiety, and arterial stiffness. Biol Psychiatry. 2011;15;69(8):795–803. doi: 10.1016/j.biopsych.2010.12.034.

24. Lekakis J, Ikonomidis I, Papoutsi Z. Selective serotonin reuptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int J Cardiol. 2010;139(2):150–158. doi: 10.1016/j.ijcard.2008.10.010



Источник: htn.almazovcentre.ru


Добавить комментарий